Please assess the completion status of the following clinical trial:

Trial Title: Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL))~* Intermediate or adverse cytogenetic risk~* Eligible for therapy with either decitabine or azacitidine~* Acceptable hematologic and organ function~Exclusion Criteria:~* AML associated with favorable risk karyotypes including inv(16), t(8;21), t(16;16), or t(15;17)~* Patients who are candidates for allogeneic stem cell transplant at the time of enrollment~* Patients with a history of one of the following myeloproliferative neoplasms: essential thrombocythemia, polycythemia vera, and primary myelofibrosis~* Received prior treatment with HMA or chemotherapy for antecedent myelodysplastic syndrome (MDS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 33A + HMA (Type: EXPERIMENTAL): 33A plus azacitidine or decitabine
- placebo + HMA (Type: ACTIVE_COMPARATOR): placebo plus azacitidine or decitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).